CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 14 enrolled
Drug / intervention
Oxycodone +4 moredrug
Likely dose
Oxycodone 5 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04223609
NCT04223609Phase 2Completed
CompareCT.gov

Non-intrusive Detection of Temporary Neurologic Impairment By Opioids

Mayo Clinic·interventional·Posted Jan 10, 2020·Updated Apr 5, 2023

In Brief

A Phase 2 clinical trial evaluating Oxycodone, Placebo, and 3 other interventions for Healthy. Completed, enrolled 14 participants across 1 site.

Detailed Summary

Research is being conducted to better understand the physiologic effects (relating to the action of a drug when taken by a healthy person) of opioid use on oculomotor (relating to the motion of the eye) dynamics and to identify the presence of characteristics consistent with a specific drug or class of drugs.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
2020202120222023202420252026
First PostedJan 10, 2020
Enrollment StartFeb 28, 2020
Primary CompletionApr 11, 2022
TodayJul 2, 2026
Enrollment to primary: 2.1 yearsPosted 6.5 years ago

Interventions

Oxycodonedrug

5 mg tablet

Placebodrug

Oxycodone-matched placebo tablet

EyeLink 1000 Plusdevice

Non-invasive video-based eye tracking system

Oculo-Cognitive Addition test (OCAT)other

Subject will have to look for numbers on a screen and add these numbers together. OCAT will be presented on a computer screen with attached eye tracking device at the bottom part.

VT3mini - Eye Tracking Technology for OEMsdevice

Non-invasive eye-tracking device